Healthcare Economics
The £500k Stranded Asset: Why the Economy Can’t Afford to Have Unemployed Doctors
A bottleneck in medical training is creating a costly economic paradox: a doctor shortage alongside unemployed medics. This is a market failure we can’t afford.
The NHS on Life Support: A Financial Diagnosis and Prescription for Tech-Fueled Recovery
A doctor’s complaint about the NHS reveals a deep economic crisis. This analysis explores how fintech, blockchain, and smart investing can fix the system.
The £1 Billion NHS Gamble: A Financial Deep Dive into the UK’s Public Health Crossroads
The UK Treasury has approved a £1bn deal for NHS job cuts to manage overspending. What does this mean for the UK economy, finance, and investors?
Redundancies and Red Ink: Decoding the NHS’s Financial Crisis and Its Ripple Effect on the UK Economy
An analysis of the NHS’s financial deal, exploring its deep impact on the UK economy, public finance, and the investment landscape.
Pfizer’s $100 Billion Gamble: Inside the High-Stakes Battle for the Weight-Loss Drug Crown
Pfizer is playing hardball in the $100B weight-loss drug market, betting its future on a pill to challenge the injectable giants, Novo Nordisk and Eli Lilly.
The Rybelsus Revelation: Why One Chart Correction Unlocks Novo Nordisk’s True Value
A minor chart correction for Novo Nordisk reveals a major lesson in financial analysis, highlighting the crucial difference between its diabetes and obesity drugs.
The Ozempic Economy: How a Weight-Loss Shot is Reshaping Markets and Killing the Business Lunch
A new class of weight-loss drugs is shaking up the economy, impacting the stock market and threatening the future of the traditional business lunch.
The Price of a Puppy: Why the UK’s Vet Industry Is a Crucial Case Study in Market Economics and Investing
The UK’s vet industry is a case study in market economics, revealing how consolidation and opacity impact prices, inviting regulatory scrutiny.
The $600M Bet: How the Global Race for Weight-Loss Drugs is Rewriting the Rules of Biotech Investing and Tapping into China’s R&D Power
A US biotech’s $600M raise for weight-loss drugs reveals a key strategy: using China for faster, cheaper clinical trials, altering biotech investing.